Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation

Détails

ID Serval
serval:BIB_F4EFD701739B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Effect of intravenous and oral calcium antagonists (diltiazem and verapamil) on sustenance of atrial fibrillation
Périodique
American Journal of Cardiology
Auteur⸱e⸱s
Shenasa  M., Kus  T., Fromer  M., LeBlanc  R. A., Dubuc  M., Nadeau  R.
ISSN
0002-9149 (Print)
Statut éditorial
Publié
Date de publication
09/1988
Volume
62
Numéro
7
Pages
403-7
Notes
Journal Article --- Old month value: Sep 1
Résumé
Both verapamil and diltiazem are used to control ventricular response during atrial fibrillation (AF). Their effect on the maintenance of AF is not known. The effects of the intravenous and oral administration of verapamil and diltiazem were investigated in 35 patients, 18 with (group I) and 17 without (group II) documented paroxysmal AF. Programmed electrical stimulation, either extra-stimuli or burst atrial pacing, was used to induce AF. In group I, the mean values of the duration of AF before and after the intravenous and oral administration of the calcium antagonists were 31 +/- 12, 112 +/- 49 and 69 +/- 25 minutes, respectively. For group II, the values were 5 +/- 3.4, 39 +/- 13 and 14 +/- 7 minutes, respectively. The differences were statistically highly significant (p less than 0.001), after both oral and intravenous administration compared with the baseline value in both groups. The data suggest that both intravenously and orally administered calcium antagonists enhance sustenance of electrically induced AF, especially in patients with spontaneous arrhythmia. Thus, in patients with paroxysmal AF, verapamil or diltiazem should be administered cautiously, because these drugs may prolong the duration of arrhythmia. Further studies are warranted to investigate the role of calcium antagonists in spontaneously occurring paroxysmal AF.
Mots-clé
Administration, Oral Adult Atrial Fibrillation/*drug therapy/physiopathology Blood Pressure Calcium Channel Blockers/*therapeutic use Diltiazem/*therapeutic use Female Humans Injections, Intravenous Male Middle Aged Time Factors Verapamil/*therapeutic use
Pubmed
Web of science
Création de la notice
28/01/2008 10:55
Dernière modification de la notice
20/08/2019 17:21
Données d'usage